ArticleFolia microbiologica2026
Investigation of chitinase B1 inhibitors targeting the cell wall biosynthetic machinery in Aspergillus fumigatus through integrated molecular dynamics and QM/MM.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aspergillus fumigatus (A. fumigatus), an opportunistic fungal pathogen, poses a significant threat to immunocompromised individuals due to increasing resistance to existing antifungal therapies. Targeting fungus-specific enzymes, such as A. fumigatus chitinase B1 (AfChiB1), which plays a critical role in cell wall remodeling, represents a promising alternative therapeutic strategy. In this study, an integrated computational workflow was employed to screen a food-derived natural compound library for potential AfChiB1 inhibitors. Three candidate inhibitors—Plantacyanin, Amentoflavone, and Conferone—along with caffeine as a reference compound, were identified through library screening followed by re-docking of DFT-optimized structures. Molecular dynamics (MD) simulations exceeding 500 ns demonstrated that Conferone exhibited the highest binding stability, supported by consistently low RMSD and RMSF values. Although Amentoflavone showed favorable QM/MM energy values, it displayed pronounced ligand drift, while Plantacyanin exhibited moderate stability. Principal component analysis and free energy landscape profiling corroborated the MD results, revealing that Conferone occupied deep energy minima with limited conformational flexibility. QM/MM calculations further confirmed the electronically favorable nature of Amentoflavone and the robust dynamic behavior of Conferone. Superimposition of initial and refined MD structures indicated stable binding conformations for all ligands. Overall, Conferone emerged as the most promising computationally predicted AfChiB1 inhibitor, although experimental validation will be required to confirm its antifungal activity. These findings highlight the antifungal potential of food-derived bioactive compounds and the value of integrated computational approaches, although experimental validation is required to substantiate these predictions.
Indexed as
Identifiers
42060100What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.